A controlled trial of idebenone in Huntington's disease

Movement Disorders

Volumn 11, Issue 5, 1996, Pages 549-554

  Ranen, Neal G ^a,e   Peyser, Carol E ^b   Coyle, Joseph T ^c   Bylsma, Frederick W ^a   Sherr, Meeia ^a   Day, Leslie ^a   Folstein, Marshal F ^d   Brandt, Jason ^a   Ross, Christopher A ^a   Folstein, Susan E ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Antioxidants; Huntington's disease; Idebenone

Indexed keywords

IDEBENONE; NOOTROPIC AGENT;

ADULT; AEROBIC METABOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE;

EID: 9544255791     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110510     Document Type: Article

References (47)

1. McHugh PR, Folstein MF. Psychiatric syndromes of Huntington's chorea: a clinical and phenomenologic study. In: Benson DF, Blumer D, eds. Psychiatric aspects of neurologic disease. New York: Grune and Stratton, 1975:267-286.
2. Folstein SE. Huntington's disease. A disorder of families. Baltimore: Johns Hopkins University Press, 1989.
3. Greenamyre JT, Shoulson I. Huntington's disease. In: Calne DB, ed. Neurodegenerative diseases. Philadelphia: Saunders, 1994:685-704.
4. Wexler N, Young AB, Tanzi R, et al. Homozygotes for Huntington's disease. Nature 1987;326:194-197.
5. HD Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable of Huntington's disease chromosomes. Cell 1993;72:971-983.
6. Albin RL, Tagle DA. Genetics and molecular biology of Huntington's disease. Trends Neurosci 1995;18:11-14.
7. Ross CA. When more is less: pathogenesis of glutamine repeat neurodegenerative diseases. Neuron 1995;15:493-496.
8. Lange HW. Quantitative changes of telencephalon, diencephalon, and mesencephalon in Huntington's chorea, post-encephalitic, and idiopathic parkinsonism. Vehr Anat Ges 1981;75:923-925.
9. Vonsattel J-P, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44: 559-577.
10. Martin JB, Gusella JF. Huntington's disease. Pathogenesis and management. N Engl J Med 1986;315:1267-1276.
11. De La Monte SM, Vonsattel J-P, Richardson EP. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 1988;47:516-525.
12. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375.
13. Hedreen JC, Peyser CE, Folstein SE, Ross CA. Neuronal loss in layers V and V1 of cerebral cortex in Huntington's disease. Neurosci Lett 1991;133:257-261.
14. Albin RL, Reiner A, Andersen KD, et al. Preferential loss of striato external paludal projection neurons in presymptomatic Huntington's disease. Ann Neurol 1992;31:425-430.
15. Hedreen JC, Ross CA. Huntington's disease. In: Clark AW, Dickson DW, eds. The primary degenerative dementias other than Alzheimer's disease. Durham: Carolina Academic Press (in press).
16. Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976;263:244-246.
17. Choi WD. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-634.
18. Miyamoto M, Murphy TH, Schnaar RL, Coyle JT. Antioxidants protect against glutamate-induced toxicity in a neuronal cell line. J Pharmacol Exp Ther 1989;250:1132-1140.
19. Beal MF, Ferrante RJ, Swartz KJ, Kowell NW. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 1991;11:1649-1659.
20. Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histological characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993;13:4181-4192.
21. Parker WD, Boyson SJ, Luder AS, Parks JK. Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 1990;40:1231-1234.
22. Mann VM, Cooper JM, Javoy-Agid F, Agid Y, Jenner P, Schapira AHV. Mitochondrial function and parental sex effect in Huntington's disease. Lancet 1990;336:749.
23. 1H magnetic resonance spectroscopy. Ann Neurol 1991;29:218-221.
24. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 1993;43:2689-2695.
25. Ranen NG, Peyser CE, Folstein SE. A physician's guide to the management of Huntington's disease: pharmacologie and non-pharmacologic alternatives. New York: HDSA, 1993.
26. Folstein SE, Peyser CE. Symptomatic treatments for Huntington's disease. In: Johnson RT, Griffin J, eds. Current therapy in neurologic disease. 4th ed. St. Louis: Mosby-Yearbook, 1993:246-250.
27. Feigin A, Kieburtz K, Shoulson I. Treatments of Huntington's disease and other choreic disorders. In: Kurlan R, ed. Treatments of movement disorders. Philadelphia: Lippincott, 1995:337-364.
28. Shoulson I, Odoroff C, Oakes D, et al. A controlled trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 1989;25:252-259.
29. Peyser CE, Folstein M, Chase GA, et al. A trial of d-alpha tocopherol in Huntington's disease. Am J Psychiatry 1995; 152:1771-1775.
30. Miyamoto M, Coyle JT. Idebenone attenuates neuronal degeneration induced by intrastriatal injection of excitotoxins. Exp Neurol 1990;108:38-45.
31. Nagaoka A. Pharmacological action of idebenone, a new therapeutic drug for cerebrovascular disorders [Japanese, English summary]. J Takeda Rex Lab 1985;44:137-155.
32. Nagaoka A. Idebenone. In: Scriabine A, ed. New cardiovascular drugs. New York: Raven Press, 1987:217-235.
33. Sugiyama Y, Fujita T. Stimulation of the respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism. FEBS Lett 1985;184:48-51.
34. Shimamura O, Sugihara H, Watanabe T, Ijichi H. Effect of CV-2619 administration on signs and symptoms in cerebrovascular disorders [Japanese]. Geriatr Med 1985;23:633-645.
35. Takauchi S, Mori T, Hosomi M, et al. A long term trial of idebenone on cerebrovascular diseases. Ther Res 1985;2: 335-356.
36. Nakona T, Miyasaka M, Mori K, Ohtaka T, Kifune Y. Effects of idebenone on electroencephalograms of patients with cerebrovascular disorders. Arch Gerontol Geriatr 1989; 8:355-366.
37. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for clinicians. J Psychiatr Res 1975;2:189-198.
38. Brandt J, Strauss ME, Larus J, Jensen B, Folstein SE, Folstein MF. Clinical correlates of dementia and disability in Huntington's disease. J Clin Neuropsychol 1984;6:401-412.
39. Bylsma FW, Rothlind J, Hall MR, Folstein SE, Brandt J. Assessment of adaptive functioning in Huntington's disease. Mov Disord 1993;8:183-190.
40. Folstein SE, Jensen B, Leigh RJ, Folstein MF. The measurement of abnormal movements: methods developed for Huntington's disease. Neurobehav Toxicol Teratol 1983;5: 605-609.
41. Penney JB Jr, Young AB, Shoulson I. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990;5:93-99.
42. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974; 11:1019-1025.
43. Benton AL. The Revised Visual Retention Test. 4th ed. New York: Psychological Corp., 1974.
44. Klove H. Clinical neuropsychology. In: Foster FM, ed. The medical clinics of North America. New York: Saunders, 1963:1647-1658.
45. Wecshler D. Wecshler Adult Intelligence Scales - revised manual. New York: Psychological Corp., 1981.
46. Reitan RM. Validity of the Trail Making Test as an indication of organic brain damage. Percept Mot Skills 1958;8:271-276.
47. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643-662.